As more data has become available, scientists have taken a closer look at how GLP-1 receptor agonists affect the brain
AEA), an endocannabinoidwhich results in an increase in AEA (Watanabe et al., 1996
[DOI] [PubMed] [Google Scholar] [117].Samanc B, Samanc Y, Tzn E, Altokka-Uzun G, Ekizolu E, z S, et al
Recently, a biased GLP-1R agonist with reduced -arrestin-1 recruitment was described as poorly insulinotropic in vivo 61 , contrasting with our observations for exendin-phe1 and several other analogs
The vascular-endothelial hypothesis posits improvements in endothelial function, nitric-oxide signaling, and microvascular perfusion, yet these vascular signatures vary dramatically between tissues and do not fully account for neuroprotective or immunomodulatory patterns